Carboplatin, epirubicin, and VP-16 chemotherapy in the treatment of small cell lung cancer

C. Gridelli, G. P. Ianniello, A. Maiorino, C. Curcio, M. D'Aprile, L. Brancaccio, S. Palmeri, M. Gentile, G. Comella, T. Pedicini, G. Airoma, E. Veltri, V. Gebbia, A. Russo, R. Casaretti, F. Giampaglia, G. Ferrante, L. Rausa, S. Iacobelli

Research output: Contribution to journalArticlepeer-review


In our study, 72 SCLC patients, 23 with limited and 49 with extensive disease, were treated with carboplatin, epirubicin, and VP-16 (CEV) chemotherapy (CBDCA 300 mg/m2 day 1, EDX 50 mg/m2 day 1, VP-16 100 mg/m2 i.v. days 1-3, every 4 weeks). Patients with limited disease were also subjected to concurrent 'split-course' chest radiotherapy followed by surgery in responders if they were not staged IIIB at diagnosis. In limited disease we obtained 96.5% objective responses (OR) with 52.5% complete responses (CR), a median survival of 14 months, with 13% long-term survivors at 30 months. In extensive disease we obtained 83.6% OR with 28.5% CR, and a median survival of 10 months. Toxicity consisted mainly of manageable myelosuppression, especially for limited disease. These data show high activity of CEV chemotherapeutic regimen.

Original languageEnglish
Pages (from-to)160-162
Number of pages3
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Issue number2
Publication statusPublished - 1994

ASJC Scopus subject areas

  • Cancer Research
  • Oncology


Dive into the research topics of 'Carboplatin, epirubicin, and VP-16 chemotherapy in the treatment of small cell lung cancer'. Together they form a unique fingerprint.

Cite this